Drug Profile
Research programme: antibody therapeutics - Novo Nordisk/Takeda
Latest Information Update: 15 Jan 2019
Price :
$50
*
At a glance
- Originator Dyax; Novo Nordisk
- Developer Novo Nordisk; Shire
- Class Antibodies
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 08 Jan 2019 Shire has been acquired and merged into Takeda
- 16 Jul 2016 No recent reports of development identified for research development in Undefined in Denmark (Parenteral)
- 22 Jan 2016 Dyax has been acquired by and merged into Shire